Takeda sees lower annual profit, generics to erode cancer drug sales - ETHealthworld.com

ETHealthworld.com
Takeda sees lower annual profit, generics to erode cancer drug sales
ETHealthworld.com
Representative image. By Sam Nussey. TOKYO - Japan's Takeda Pharmaceutical Co Ltd on Monday forecast a 17 percent drop in operating profit for the year through March 2019 as blood cancer drug Velcade looks set to face generic competition in the ...and more »